EUVIMEDEUVIMED entdecken
Open Access

Microbial riboflavin inhibits ceramide synthase 3 to lower ceramide (d18:1/26:0) and delay colorectal cancer progression

Ruize Qu, Yi Zhang, Bora Kim, Guangyi Zeng, Pengcheng Wang, Weike Shaoyong, Ying Huang, Wanwan Guo, Yang Chen, Ping Wang, Qing Yang, Siyi Lu und 16 weitere

Cell Metabolism · 2025-09 · 37 (9) · 1852-1869.e8

DOI: 10.1016/j.cmet.2025.06.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Metabolism, 2025-09. Verfasst von Ruize Qu und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, Cancer Center, Beijing Key Laboratory for Interdiscip…. Hauptthemen laut MEDLINE: Ceramides, Colorectal Neoplasms, Riboflavin, Sphingosine N-Acyltransferase. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Key Research and Development Program of China, National Key Clinical Specialty Discipline Construction Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ceramide metabolism dysregulation links to colorectal cancer (CRC) progression, yet the mechanism remains unknown. d18:1/26:0 ceramide (C26) levels were elevated in patients with CRC and mouse models, which activated epidermal growth factor receptor (EGFR) by binding its extracellular region to promote cancer cell proliferation. The rise of C26 levels was mainly driven by heightened ceramide synthase 3 (CERS3) activity. High CERS3 expression generally accelerated tumor progression, yet some patients exhibited significant heterogeneity, suggesting endogenous metabolites available to affect CERS3 activity. We found that the abundance of Bacteroides cellulosilyticus affects tumor heterogeneity by producing riboflavin that inhibits CERS3 activity, thus delaying CRC progression. Moreover, aclidinium bromide, an FDA-approved drug, exhibited significant inhibitory effects on CERS3 activity, suggesting its potential application in CRC treatment. These findings elucidate the metabolic pathways and mechanisms underlying ceramide's impact on CRC, highlighting that targeting CERS3 inhibition represents a promising therapeutic strategy for CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeramidesColorectal NeoplasmsRiboflavinSphingosine N-AcyltransferaseHumansAnimalsMiceDisease ProgressionCell Line, TumorFemaleMaleCell ProliferationOxidoreductases

Substanzen

CeramidesRiboflavinSphingosine N-Acyltransferasedihydroceramide desaturaseOxidoreductases

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, Cancer Center, Beijing Key Laboratory for Interdisciplinary Research in Gastrointestinal Oncology (BLGO), Peking University…
  • Department of General Surgery, Peking University Third Hospital, Beijing 100191, China.
  • Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
  • Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China.
  • CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.
  • State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medici…

Förderung

  • Intramural NIH HHS
  • National Key Research and Development Program of China
  • National Key Clinical Specialty Discipline Construction Program of China
  • National Cancer Institute
  • National Natural Science Foundation of China
  • Peking University
  • China Association for Science and Technology
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Qu, R., Zhang, Y., Kim, B., Zeng, G., Wang, P., Shaoyong, W., Huang, Y., Guo, W., Chen, Y., Wang, P., Yang, Q., Lu, S., Zhou, X., Weng, J., Xu, J., Lin, J., Wang, K., Ma, Y., Takahashi, S., …, & Sun, L. (2025). Microbial riboflavin inhibits ceramide synthase 3 to lower ceramide (d18:1/26:0) and delay colorectal cancer progression. Cell Metabolism, 37(9), 1852-1869.e8. https://doi.org/10.1016/j.cmet.2025.06.002

Vancouver

Qu R, Zhang Y, Kim B, Zeng G, Wang P, Shaoyong W, et al. Microbial riboflavin inhibits ceramide synthase 3 to lower ceramide (d18:1/26:0) and delay colorectal cancer progression. Cell Metabolism. 2025;37(9):1852-1869.e8. doi:10.1016/j.cmet.2025.06.002

BibTeX
@article{Qu2025,
  author = {Qu, Ruize and Zhang, Yi and Kim, Bora and Zeng, Guangyi and Wang, Pengcheng and Shaoyong, Weike and Huang, Ying and Guo, Wanwan and Chen, Yang and Wang, Ping and Yang, Qing and Lu, Siyi and Zhou, Xin and Weng, Jing and Xu, Jinkun and Lin, Jun and Wang, Kai and Ma, Yanpeng and Takahashi, Shogo and Luo, Yuhong and Yu, Xiaoting and Krausz, Kristopher W and Pang, Yanli and Hong, Tianpei and Zhang, Zhipeng and Fu, Wei and Gonzalez, Frank J and Sun, Lulu},
  title = {Microbial riboflavin inhibits ceramide synthase 3 to lower ceramide (d18:1/26:0) and delay colorectal cancer progression},
  journal = {Cell Metabolism},
  year = {2025},
  volume = {37},
  number = {9},
  pages = {1852--1869.e8},
  doi = {10.1016/j.cmet.2025.06.002}
}
Kostenlos starten →